After an extensive waiting period, Augmentiqs received official notice of a U.S. patent. The patent is awarded for innovation and usefulness, highlighting the unique method via which Augmentiqs can improve pathology.

Gabe Siegel, Augmentiqs CEO and co-founder, “So long as the glass slide remains the raw data in pathology, Augmentiqs represents an easy, cost-efficient and patented method for harnessing teh benefits of AI within the classic pathology workflow.”

The company express gratitude to its IP attorneys at Smith, Gambrell & Russell for their hard-work, dedication and whole-hearted rising to the occassion.